Plan B ECP receives Canadian approval

Plan B, the levonorgestrel emergency contraceptive pill (ECP) from Women’s Capital Corp. of Bellevue, WA, has received approval for Canadian distribution. The Canadian Therapeutic Products Programme’s notice of compliance permitting the sale of the drug was announced by Paladin Labs of Montreal. Paladin holds exclusive Canadian distribution rights for the ECP. The company will launch Plan B in the second quarter of this year, according to Jonathan Goodman, Paladin president and CEO.

Preven, the ethinyl estradiol/levonorgestrel ECP from Gynétics of Belle Mead, NJ, is now on the Canadian market. It is distributed by Roberts Pharmaceutical Canada of Toronto.